<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813799</url>
  </required_header>
  <id_info>
    <org_study_id>DA9801_DN_II</org_study_id>
    <nct_id>NCT01813799</nct_id>
  </id_info>
  <brief_title>Study of DA-9801 to Treat Diabetic Neuropathic Pain</brief_title>
  <official_title>A Multicenter, Placebo-controlled, Randomized, Double-blind, Phase II Clinical Trial With Diabetic Neuropathy Patients is Designed to Evaluate the Safety and Efficacy of the DA-9801 Tablet for Neuropathic Pain and to Decide Optimal Dose.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II dose-ranging study to evaluate the effectiveness and safety of DA-9801 in
      the treatment of pain associated with diabetic neuropathy. Subjects will receive either
      300mg, 600mg, 900mg or placebo, three times daily for eight weeks. During treatment, pain
      score by Likert numerical rating scale, Patient Global Impression of Improvement (PGI-I) and
      Change in Clinical Global Impression(CGI)are accessed to evaluate the effectiveness.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in average 24-h pain intensity (Likert scale) between before and after IP administration</measure>
    <time_frame>8 weeks</time_frame>
    <description>Subject records the average pain intensity for the past 24 hours in the patient diary at the same time every morning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter-group difference in average 24-h pain intensity (Likert scale)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The mean value of the last one week since the date of visit was calculated to compare the difference between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Most severe mean pain intensity (Likert Scale)</measure>
    <time_frame>4, 8 weeks</time_frame>
    <description>Subject records the most severe pain intensity for the past 24 hours in the patient diary at the same time every morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overnight pain intensity (Likert Scale)</measure>
    <time_frame>4, 8 weeks</time_frame>
    <description>Subject records the overnight pain intensity during the previous night in the patient diary at the same time every morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Impression of improvement (1 point ~ 7 point)</measure>
    <time_frame>4, 8 weeks</time_frame>
    <description>Subject evaluated the level of symptom improvement during the visits after IP administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of severity (1 point ~ 7 point)</measure>
    <time_frame>4, 8 weeks</time_frame>
    <description>Investigator evaluated the level of symptom severity when a subject visited the institution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily dose of acetaminophen</measure>
    <time_frame>everyday(-2 weeks~0), everyday(0~8 weeks)</time_frame>
    <description>Subject records dose of acetaminophen during the past 24 hours in patient diary at the same time every</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>DA-9801 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-9801 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-9801 900mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-9801 300mg</intervention_name>
    <description>300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.</description>
    <arm_group_label>DA-9801 300mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-9801 600mg</intervention_name>
    <description>600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.</description>
    <arm_group_label>DA-9801 600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-9801 900mg</intervention_name>
    <description>900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.</description>
    <arm_group_label>DA-9801 900mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the age of 20 ~ 70

          -  Type I or Type II Diabetes

          -  HbA1c â‰¤11%

          -  Patients with diabetic neuropathic pain for at least 3 months

          -  Patients corresponding to average pain level of 4 points or more for 24 hours
             evaluated with 11-point Likert scale

        Exclusion Criteria:

          -  neuropathic pain due to other causes or another stronger pain other than neuropathic
             pain

          -  abnormal in blood pressure, weight, ALT/AST, Serum creatinine

          -  positive reaction in HIV, HBV, or HCV

          -  experience of suicide try or Mental Illness Medical History

          -  BDI(Beck Depression Inventory) grade exceeding 21 points chronic alcohol abuse history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bongyeon Cha, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyeok Sang Gwon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Yeouido St. Mary's Hopspital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Inkyung Jeong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangdong Kyunghee University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ji Hyeon Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Daegu Catholic University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeong Guk Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>In Ju Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Busan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Young Min Cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chun Hee Jung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Wonju Christian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jyeong Hyeon Park, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mun Seok Nam, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong Hyeok Cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Min Kyong Moon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chong Hwa Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sejong Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kwan Pyo Ko, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeju National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>April 14, 2019</last_update_submitted>
  <last_update_submitted_qc>April 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Neuropathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 22, 2019</submitted>
    <returned>July 23, 2019</returned>
    <submitted>May 12, 2020</submitted>
    <returned>May 21, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

